Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Sponsor: Novartis Vaccines
Listed as NCT01345721, this PHASE3 trial focuses on Meningococcal Disease and remains completed. Sponsored by Novartis Vaccines, it has been updated 9 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Vaccines
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Am Teich 11, Neumuenster, Germany , Boyneburgstr 7, Eschwege, Germany , GroBbottwarer Str 47, Oberstenfeld, Germany , Heinrichstrasse 16 A, Fulda, Germany , Hellersdorfer Str 237, Berlin, Germany , Kirchstrasse 2, Bonnigheim, Germany , Murnauer Str 3, Weilheim, Germany , Rathausstr 6, Gluecksburg, Germany , Schoenwalder Str 28, Berlin, Germany , Stuttgarter Strasse 74, Stuttgart Feuerbach, Germany and 1 more location